Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing novel therapies for kidney diseases, particularly addressing unmet needs in hyperphosphatemia and acute kidney injury.[1][2][3] Its lead candidate, oxylanthanum carbonate, is a next-generation phosphate-binding agent under FDA review for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis, while UNI-494 targets acute kidney injury (AKI).[1][2][6] The company serves patients with renal conditions, caregivers, and the broader nephrology community, tackling critical issues like uncontrolled phosphate levels that contribute to cardiovascular risks and mortality in dialysis patients, with over 1 in 7 U.S. adults affected by kidney disease.[4] Growth momentum includes recent Q3 2025 financial results, new data presentations at the American Society of Nephrology Kidney Week 2025, and an agile pipeline leveraging licensing partnerships.[2][4]
Founded in 2016 and headquartered in Los Altos, California, Unicycive was established by Dr. Shalabh K. Gupta, M.D., MPA, who serves as Chairman, CEO, and President, bringing expertise in biotechnology and medicine.[1][3] The idea emerged from identifying overlooked opportunities in kidney care, driven by the high prevalence of undiagnosed CKD—9 out of 10 cases unknown—and gaps in treatments for conditions like hyperphosphatemia and AKI.[4] Early traction came through strategic license agreements, including with Shilpa Medicare Ltd. for oxylanthanum carbonate, Sphaera Pharma for UNI-494 components, and others for development and commercialization, enabling rapid preclinical and clinical advancement.[1][3] The company went public via IPO in July 2021, marking a pivotal shift to clinical-stage development with a lean team of 23 employees.[1]
Unicycive rides the wave of advancing nephrology biotech amid rising CKD prevalence, fueled by aging populations, diabetes, and hypertension, with market forces favoring novel phosphate binders as current therapies fall short in efficacy and tolerability.[1][4] Timing is critical as FDA review for oxylanthanum carbonate nears potential approval, addressing a hyperphosphatemia market projected to grow with dialysis patient increases, while AKI therapies fill gaps in hospital critical care.[2][6] The company influences the ecosystem by pioneering efficient drug development for fibrosis and inflammation in renal/liver diseases, partnering globally to accelerate U.S. commercialization, and contributing data to conferences like ASN Kidney Week, potentially reshaping standards for the 550,000+ U.S. dialysis patients.[2][4]
Unicycive's path hinges on oxylanthanum carbonate's FDA trajectory post-Q3 2025 updates and UNI-494's clinical progression, with trends like precision nephrology, AI-driven trials, and expanded orphan indications likely propelling growth.[2][4] Success could position it as a dialysis staple, evolving its influence through partnerships and pipeline expansion into metabolic diseases. As a biotech tackling kidney care's "overlooked opportunities," its momentum underscores how focused innovation delivers when patients can't wait.[4]
